Asian markets ended lower on Wednesday. Japanese shares ended lower with the stronger safe-haven yen after US technology stocks sold off overnight and a leading corona virus vaccine candidate faced delay. Final clinical trials for a corona virus vaccine, developed by drug maker AstraZeneca and Oxford University have been put on hold after a participant had a suspected adverse reaction in the UK. Further, heightened trade tensions between Washington and Beijing, and falling oil prices also curbing risk appetite. Chinese inflation data for August showed the producer price index declined 2.0% in August from a year earlier, and in line with expectations; while the consumer price index in August rose 2.4% as compared with a year ago.
Asian Indices | Last Trade | Change in Points | Change in % |
Shanghai Composite | 3,254.63 | -61.79 | -1.86 |
Hang Seng | 24,468.93 | -155.41 | -0.63 |
Jakarta Composite | 5,149.38 | -94.69 | -1.81 |
KLSE Composite | 1,496.72 | -22.60 | -1.49 |
Nikkei 225 | 23,032.54 | -241.59 | -1.04 |
Straits Times | 2,499.33 | -5.43 | -0.22 |
KOSPI Composite | 2,375.81 | -26.10 | -1.09 |
Taiwan Weighted | 12,608.58 | -54.98 | -0.43 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: